-
Mashup Score: 0
WASHINGTON — Pain in patients scheduled for total knee arthroplasty demonstrates no relation to physical activity, suggesting pain relief alone may not improve activity after the procedure, according to a speaker at ACR Convergence 2024. “Published data suggest that physical activity uptake among persons with knee OA is low, and low physical activity has been attributed to
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet
-
Mashup Score: 1
WASHINGTON — SGLT2 inhibitors can reduce the need for urate-lowering and flare therapies, and lower the odds of gout-centric medical visits, in patients with gout alongside type 2 diabetes, according to a speaker at ACR Convergence 2024.“Although SGLT2 inhibitors were initially approved for diabetes, of course, now we’ve discovered many additional benefits — both
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
🗨️ “This large population-based study ... suggests that the urate-lowering benefit resulting from initiation of SGLT2 inhibitors reduces the need for initiation of urate-lowering therapy” More from Dr. Gregory Challener @MassGeneralNews at #ACR24 👇 https://t.co/b9l11it2Vu
-
-
Mashup Score: 1
WASHINGTON — Inebilizumab is safe and effective in IgG4-related disease, significantly reducing the chance of flare through 52 weeks compared with placebo, according to data presented at ACR Convergence 2024. “This trial, a culmination of 15 years on the concept that B-cell depletion might be an important therapeutic approach to the treatment of IgG4-related disease (IgG4-RD), is a
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
🚨 #ACR24 data: #Inebilizumab is safe and effective in #IgG4RD, significantly reducing flare risk through 52 weeks vs. placebo Learn more from investigator Dr. John Stone @MassGeneralNews @harvardmed ⬇️ https://t.co/NBgzOGwFxJ
-
-
Mashup Score: 1
WASHINGTON — Inebilizumab is safe and effective in IgG4-related disease, significantly reducing the chance of flare through 52 weeks compared with placebo, according to data presented at ACR Convergence 2024. “This trial, a culmination of 15 years on the concept that B-cell depletion might be an important therapeutic approach to the treatment of IgG4-related disease (IgG4-RD), is a
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
🚨 #ACR24 data: #Inebilizumab is safe and effective in #IgG4RD, significantly reducing flare risk through 52 weeks vs. placebo Learn more from investigator Dr. John Stone @MassGeneralNews @harvardmed ⬇️ https://t.co/NBgzOGwFxJ
-
-
Mashup Score: 0Medication-assisted weight loss boosts patient-reported outcomes in rheumatic disease - 6 day(s) ago
WASHINGTON — Patients who use medication or surgery to achieve at least 5% weight loss demonstrate greater improvements in patient-reported outcomes across various rheumatic diseases, according to data presented at ACR Convergence 2024. “GLP-1 agonist use has been expanding as an effective medical therapy for weight loss,” Thomas Riley, MD, a postdoctoral fellow at the
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
🗨️ “Those with obesity, really regardless of their underlying condition, are noting improvements in their disease activity" More from Dr. Thomas Riley @Penn on medication-assisted weight loss in rheumatic disease at #ACR24 👇 https://t.co/DjAIVaO59S
-
-
Mashup Score: 1
WASHINGTON — Chimeric antigen receptor nature-killing cell therapy achieved “efficacy, persistence and super safety” in a small cohort of patients with systemic lupus erythematosus, according to data presented at ACR Convergence 2024.“The unique biological characteristics of NK cells provide us with alternative to treat SLE with super safety,” Qian Hao, PhD,
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
🗨️ “The unique biological characteristics of NK cells provide us with alternative to treat SLE with super safety" #ACR24 #rheumtwitter https://t.co/Rx2X1U65hl
-
-
Mashup Score: 2Mortality similar after single- vs double-lung transplant in autoimmune disease with ILD - 10 day(s) ago
WASHINGTON — Patients with systemic autoimmune rheumatic disease who develop interstitial lung disease demonstrate similar 1-year mortality risks following either single- or double-lung transplant, according to data.The finding, presented at ACR Convergence 2024, suggests that, for patients with late-stage lung disease from ILD and systemic autoimmune rheumatic diseases (SARDs), single-lung
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
🫁 SARD patients with interstitial lung disease show similar 1-year mortality risk with either single- or double-lung transplant #rheumtwitter More from Dr. Harry Hurley @EinsteinMed at #ACR24 👇 https://t.co/UEs9a5ChKk
-
-
Mashup Score: 5Delayed methotrexate start improves pneumococcal vaccine response in rheumatoid arthritis - 11 day(s) ago
WASHINGTON — Delaying methotrexate initiation for 1 month after pneumococcal vaccination improves humoral response in patients with rheumatoid arthritis, according to data presented at ACR Convergence 2024. “As you know, vaccination against pneumococcus is recommended in patients with RA being treated with methotrexate,” Jacques Morel, MD, of the University Hospital of
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
🗨️“This is the first study to show it is better to vaccinate RA patients with PCV13 1 month before #methotrexate initiation with no impact on RA disease activity” More from Dr. Jacques Morel @CHU_Montpellier at #ACR24 ⬇️ https://t.co/gAU1Sf0ol9
-
-
Mashup Score: 0
WASHINGTON — Early triple therapy may be the most effective strategy for lupus nephritis, according to the new 2024 American College of Rheumatology Guideline for the Screening, Treatment, and Management of Lupus Nephritis.The 2024 document, which was presented in a press conference at ACR Convergence 2024, includes 41 recommendations overall.
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
💡 Early triple therapy may be the most effective strategy for #lupus nephritis That's just one of 41 recommendations in @ACRheum's newest guidelines Here's a rundown from #ACR24 ⬇️ https://t.co/mtRp3m0NkY
-
-
Mashup Score: 1Early methotrexate course may prevent rheumatoid arthritis in some high-risk patients - 12 day(s) ago
WASHINGTON — An early, 1-year course of methotrexate may prevent anti-citrullinated protein autoantibody-negative rheumatoid arthritis in high-risk patients with clinically suspect arthralgia, noted a presenter at ACR Convergence 2024. “Patients with clinically suspect arthralgia (CSA) are at risk for rheumatoid arthritis,” Quirine Dumoulin, MD, of Leiden University Medical
Source: www.healio.comCategories: General Medicine News, RheumatologyTweet-
🕐 An early, 1-year course of methotrexate may prevent ACPA-negative rheumatoid arthritis in high-risk patients with clinically suspect arthralgia More from Dr. Quirine Dumoulin @UniLeidenNews at #ACR24 ⬇️ https://t.co/iPSvlZAJud
-
💡 “Contrary to common perception, we did not find an association between pain severity and objectively measured physical activity" 🏃♂️ More from Dr. Elena Losina @BrighamWomens at #ACR24 👇 https://t.co/j48ohm1NwR